Identity
- Security key
- 23850
- Ticker
- XCUR
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2018-05-09
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- XCUR
Detail
Enriched 2026-08-14 20:47
- Market cap
- $8,286,118.1
- Shares outstanding (class)
- 6,373,937
- Shares outstanding (weighted)
- 6,373,937
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 8
- Location
- CHICAGO, IL
- Homepage
- https://www.exicuretx.com
- Description
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.
Market cap and share counts drift.